Nasus Pharma (NSRX) Debt to Equity (2024)

Nasus Pharma (NSRX) reported Debt to Equity of -$0.56 for Q4 2024.

Nasus Pharma (NSRX) Debt to Equity (2024) Analysis & Trends

Nasus Pharma has reported Debt to Equity for 1 years, with the latest figure at -$0.56 in Q4 2024.

For the quarter ending Q4 2024, Debt to Equity changed N/A year-over-year to -$0.56; the trailing twelve-month figure through Dec 2024 stood at -$0.56 (changed N/A YoY), and the FY2024 full-year result was -$0.56, changed N/A from the prior year.
Debt to Equity for Q4 2024 stood at -$0.56.
The five-year high for Debt to Equity was -$0.56 in Q4 2024, with the low at -$0.56 in Q4 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	1.39
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	0.68
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	-9.70
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	1.07
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	6.24
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	0.94
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	0.72
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	2.22
10	Nasus Pharma	24.83 Mn	20.55 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2024	-0.56